XM does not provide services to residents of the United States of America.
E
E

EDP

News

Brazil tightens rules to renew energy distribution concessions

Brazil tightens rules to renew energy distribution concessions June 20 (Reuters) - The Brazilian government issued on Thursday tighter guidelines for the extension of energy distribution contracts, easing the advanced cancellation of concessions and allowing the country to limit pay out from firms that do not comply with the rules. The energy ministry has been working since 2022 on the guidelines, which affect international energy groups such as Italy's Enel ENEI.MI and Portugal's EDP EDP.LS , a
E
E

Norges Bank Increased Its Stake To 5.06% Of EDP's Share Capital

BRIEF- Norges Bank Increased Its Stake To 5.06% Of EDP's Share Capital June 18 (Reuters) - Edp SA EDP.LS : NORGES BANK INCREASED ITS SHAREHOLDER PARTICIPATION TO 5.06% OF EDP’S SHARE CAPITAL AND OF RESPECTIVE VOTING RIGHTS NORGES BANK PREVIOUSLY HELD 4.95% STAKE IN EDP Source text: https://tinyurl.com/2p8e6tnh Further company coverage: EDP.LS (Gd
E

EDP Completes 100 Mln Euro Sale of Energia Asia Stake

REFILE-BRIEF-EDP Completes 100 Mln Euro Sale of Energia Asia Stake Adds name of the company in the headline June 18 (Reuters) - EDP Energias de Portugal SA EDP.LS : SAID ON MONDAY IT COMPLETES SALE OF REMAINING 50% STAKE IN ENERGIA ÁSIA TO CHINA THREE GORGES FOR 100 MILLION EUROS TRANSACTION LETS EDP REALLOCATE CAPITAL TO CORE ACTIVITIES, ALIGNING
E

Jefferies cuts EDPR to 'hold', reiterates 'buy' for EDP

BUZZ-Jefferies cuts EDPR to 'hold', reiterates 'buy' for EDP ** Jefferies downgrades Portugal's wind energy producer EDP Renovaveis EDPR.LS to "hold" from "buy" as current valuations limit its potential upside ** The brokerage believes that current holding discount (c.27%) to EDPR's market value is excessive and remains cautious because of expected
E
E

4Imprint, AstraZeneca, Bellway

EUROPE RESEARCH ROUNDUP-4Imprint, AstraZeneca, Bellway June 5 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including 4Imprint, AstraZeneca and Bellway, on Wednesday. HIGHLIGHTS * 4Imprint FOUR.L : HSBC raises target price to 6370p from 6060p * AstraZeneca AZN.L : HSBC raises target price to 14070p from 12950p * Bellway Plc BWY.L : Berenberg raises target price to 2900p from 2500p * Berkeley Group BKGH.L : Berenberg raises target price to
A
A
B
B
B
B
B
C
E
G
G
H
H
I
M
M
O
P
R
R
S
B
E
M
N
P
R
S
T

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.